title: Impaired IL-4 phosphorylation of STAT6 in EBV transformed B-cells.
abstract: BACKGROUND
  The Interleukin-4 signal transducer and activator of transcription 6 (IL-4-STAT6) signaling pathway plays a pivotal role in regulation of gene transcription. We have previously identified a defective STAT6 activational phenotype in response to IL-4 in patients from our familial Inflammatory Bowel Disease registry. This has been termed Stat6(null) and Stat6(high) is the normal phenotype. The purpose of this study was to investigate the defect in Stat6 activation in Stat6(null) cells.
  
  
  METHODS
  Stat6(null) and Stat6(high) Epstein Barr virus transformed cell lines were stimulated with 10 ng/mL of IL-4 for 0, 10, 30, or 60 min and cytoplasmic and nuclear proteins harvested. Western blot for STAT6, phosphorylated STAT6 (pSTAT6), Janus Kinase (Jak)1 and Jak3 was performed. Cells were also cultured for 48 h and interferon gamma (IFNgamma) measured in the supernatant. Additional cells were cultured with 20 ng/mL of IFNgamma for 90 min or 5 ug of antibody to IFNgamma for 48 h, and then stimulated with IL-4.
  
  
  RESULTS
  There were no differences in cytoplasmic STAT6 in Stat6(null)versus Stat6(high) cells. In Stat6(high) cells, STAT6 was rapidly phosphorylated and translocated to the nucleus. In Stat6(null) cells there was minimal phosphorylation and translocation of pSTAT6 to the nucleus. Spontaneous secretion of IFNgamma by Stat6(null) cells was significantly higher than Stat6(null) cells. Addition of IFNgamma decreased pSTAT6 in Stat6(high) cells to Stat6(null) levels while blocking IFNgamma increased baseline pSTAT6 in Stat6(null) cells to levels similar to Stat6(high) cells.
  
  
  CONCLUSIONS
  This suggests that the spontaneously produced IFNgamma in the Stat6(null) cell lines suppresses STAT6 function and creates the Stat6(null) phenotype.
authors.affiliation: Department of Surgery, The Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, Pennsylvania 17033, USA. lporitz@psu.edu
authors.forename: Lisa S
authors.initials: LS
authors.lastname: Poritz
authors.forename: Wen Jie
authors.initials: WJ
authors.lastname: Zhang
authors.forename: Jennifer
authors.initials: J
authors.lastname: Thompson
authors.forename: Morgan
authors.initials: M
authors.lastname: Boyer
authors.forename: Clarence
authors.initials: C
authors.lastname: Clark
authors.forename: Walter A
authors.initials: WA
authors.lastname: Koltun
mesh_terms: D001402:B-Lymphocytes / Q000187:drug effects / Q000502:physiology* / Q000821:virology; D015153:Blotting, Western; D002460:Cell Line; D002461:Cell Line, Transformed; D004854:Herpesvirus 4, Human / Q000502:physiology*; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology; D015847:Interleukin-4 / Q000378:metabolism* / Q000494:pharmacology; D053613:Janus Kinase 1 / Q000378:metabolism; D053616:Janus Kinase 3 / Q000378:metabolism; D008214:Lymphocytes / Q000187:drug effects / Q000502:physiology*; D010766:Phosphorylation; D019948:Receptors, Interleukin-4 / Q000502:physiology*; D012042:Registries; D050800:STAT6 Transcription Factor / Q000172:deficiency / Q000378:metabolism*
chemical_list: D019948:Receptors, Interleukin-4; D050800:STAT6 Transcription Factor; C494101:STAT6 protein, human; D015847:Interleukin-4; D007371:Interferon-gamma; C507904:JAK1 protein, human; D053613:Janus Kinase 1; D053616:Janus Kinase 3